Advanced search
Publication Cover
Journal of Chemotherapy Volume 30, 2018 - Issue 6-8
Submit an article Journal homepage
358
Views
4
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

In-vitro activities of imipenem–colistin, imipenem–tigecycline, and tigecycline–colistin combinations against carbapenem-resistant Enterobacteriaceae*

Devrim DundarDepartment of Medical Microbiology, Faculty of Medicine, Kocaeli University, Turkey, Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2073-7168View further author information
ORCID Icon,
Zehra DuymazDepartment of Medical Microbiology, Faculty of Medicine, Kocaeli University, Turkey, View further author information
,
Serpil GencDepartment of Medical Microbiology, Faculty of Medicine, Kocaeli University, Turkey, View further author information
,
Doganhan Kadir ErDepartment of Medical Microbiology, Institute of Health Sciences, Kocaeli University, Turkey, ORCID Iconhttp://orcid.org/0000-0001-5237-7983View further author information
ORCID Icon,
Arzu İrvemDepartment of Medical Microbiology, Istanbul Umraniye Training and Research Hospital, Turkey, View further author information
&
Neslisah KandemirDepartment of Molecular Biology and Genetics, Istanbul Technical University, TurkeyORCID Iconhttp://orcid.org/0000-0002-1181-0047View further author information
ORCID Icon
Pages 342-347 | Received 09 Mar 2018, Accepted 20 Aug 2018, Published online: 19 Jan 2019

References

  • Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(7):862–72. doi: 10.1111/1469-0691.12697
  • Tangdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501–12. doi: 10.1111/joim.12342
  • Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69(9):2305–9. doi: https://doi.org/10.1093/jac/dku168
  • Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94. doi: 10.1128/AAC.01733-10
  • Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65(5):1019–27. doi: 10.1093/jac/dkq069
  • . Performance standards for antimicrobial susceptibility testing: twenty fourth informational supplement. [M100-S21]. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
  • . EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, May 2017. Available from: http://www.eucast.org
  • Moody J. Synergism testing: Broth microdilution checkerboard and broth macrodilution methods. In: , editor. Clincal Microbiology Procedures Handbook. Washington: ASM Press;2004. p. 5.12.1-23.
  • Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11(2):159–77. doi: 10.1586/eri.12.162
  • Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(6):3541–6. doi: 10.1128/AAC.02449-14
  • Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56(6):3395–8. doi: 10.1128/AAC.06364-11
  • Lee GC, Burges DS. Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae. J Clin Med Res. 2013;5(2):97–100. doi: 10.4021/jocmr1220w
  • Pournaras S, Vrioni G, Neou E, Dendrinos E, Poulou A, Tsakris A. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37(3):244–7. doi: 10.1016/j.ijantimicag.2010.10.031
  • Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother. 2009;53(5):2133–5. doi: 10.1128/AAC.01271-08
  • Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104–11. doi: 10.1128/AAC.01230-13
  • Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 2012;31(5):695–701. doi: 10.1007/s10096-011-1360-5
  • Evren E, Azap OK, Çolakoğlu Ş, Arslan H. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis. 2013;76(3):335–8. doi: 10.1016/j.diagmicrobio.2013.04.004
  • Kmeid JG, Youssef MM, Kanafani ZA, Kanj SS. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther. 2013;11(12):1355–62. doi: 10.1586/14787210.2013.846215
  • Clock SA, Tabibi S, Alba L, Kubin CJ, Whittier S, Saiman L. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2013;76(3):343–6. doi: 10.1016/j.diagmicrobio.2013.03.014

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.